pharmaphorum July 29, 2024
Phil Taylor

Otsuka has teamed up with one of the innovation arms of the NHS to explore how a digital therapeutic (DTx) for major depressive disorder (MDD) could be deployed within the health service.

The alliance with Health Innovation Oxford & Thames Valley (Oxford HIN) is focusing on Care for MDD, an app-based DTx co-developed by Otsuka and digital health specialist Click Therapeutics. It is an adapted version of a DTx that was recently approved by the FDA in the US under the Rejoyn brand.

Alongside Oxford HIN, Otsuka will monitor patient and healthcare practitioner feedback on the real-world use of Care for MDD, which combines a cognitive behavioural therapy (CBT) course with a cognitive-emotional training method known as Emotional Faces Memory...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: Apps, Digital Health, Health System / Hospital, Mental Health, Partnerships, Patient / Consumer, Provider, Technology, Trends
Related Articles:
AI Personas Of Synthetic Clients Spurs Systematic Uplift Of Mental Health Therapeutic Skills
Federal Discretionary Spending To Address Substance Use Disorders: How Big A Shift?
Preparing to be 80: Important Considerations for Psychiatry and Society
Telehealth Claims Are Declining. What’s Next For Virtual Mental Health Care?
Why U.S. middle-aged adults report more loneliness and poorer health than peers abroad

Share Article